Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Boston, United States; Harvard Medical School, Boston, United States
Charles K Kaufman
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, United States; Department of Developmental Biology, Washington University School of Medicine, St. Louis, United States
Beste Kinikoglu
Center for Regenerative Medicine, Massachusetts General Hospital, Boston, United States; Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, United States
Jonathan Michael
Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Boston, United States
Song Yang
Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Boston, United States
Christopher D′Amato
Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Boston, United States
Sasja Blokzijl-Franke
Hubrecht Institute, Koninklijke Nederlandse Akademie van Wetenschappen, University Medical Center Utrecht, Utrecht, Netherlands
Jeroen den Hertog
Hubrecht Institute, Koninklijke Nederlandse Akademie van Wetenschappen, University Medical Center Utrecht, Utrecht, Netherlands
Thorsten M Schlaeger
Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Boston, United States
Yi Zhou
Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Boston, United States
Eric Liao
Harvard Medical School, Boston, United States; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, United States; Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, United States; Harvard Stem Cell Institute, Cambridge, United States
Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Boston, United States; Harvard Medical School, Boston, United States; Harvard Stem Cell Institute, Cambridge, United States
The neural crest is a dynamic progenitor cell population that arises at the border of neural and non-neural ectoderm. The inductive roles of FGF, Wnt, and BMP at the neural plate border are well established, but the signals required for subsequent neural crest development remain poorly characterized. Here, we conducted a screen in primary zebrafish embryo cultures for chemicals that disrupt neural crest development, as read out by crestin:EGFP expression. We found that the natural product caffeic acid phenethyl ester (CAPE) disrupts neural crest gene expression, migration, and melanocytic differentiation by reducing Sox10 activity. CAPE inhibits FGF-stimulated PI3K/Akt signaling, and neural crest defects in CAPE-treated embryos are suppressed by constitutively active Akt1. Inhibition of Akt activity by constitutively active PTEN similarly decreases crestin expression and Sox10 activity. Our study has identified Akt as a novel intracellular pathway required for neural crest differentiation.